Menopausal hormone therapy
Hormone therapy for menopausal symptoms, benefits and risks.
Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 309, 281, 295, 364, 402.
New guidelines and consensus this year
- Statement in Support of Excluding Turner Syndrome and Klinefelter Syndrome from Variations of Sex Development and Gender Dysphoria for the Purpose of Government Policy Decision-Making: A Position StatementHorm Res Paediatr2026 Aug 12
- Prevention of Heart Failure in Women: An Expert Consensus Statement on Sex-Specific Risk FactorsEur J Heart Fail2026 Jul 3
- FIGO best practice recommendations for the mental health of women at menopausal ageInt J Gynaecol Obstet2026 May
- Expert opinion by the Italian Society of Gynecology of the Third Age (SIGiTE) and the Italian Society of Menopause (SIM) on diagnosis and treatment of premature ovarian insufficiencyMinerva Endocrinol (Torino)2026 Mar
- Clinical practice guidelines for the management of differences of sex development in JapanEndocr J2026 Feb 2
All papers from the last 12 months
963 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- The history of the discovery of estetrolJ Steroid Biochem Mol Biol2027 JanPMID 42632428Review
- Estrogen deficiency-induced lipid dysregulation in menopause: Mechanisms, metabolic consequences, and therapeutic strategiesJ Steroid Biochem Mol Biol2027 JanPMID 42580603Review
- Optimizing estradiol serum levels for optimal skeletal and cardiovascular health during transdermal menopausal hormone therapyGynecol Endocrinol2026 Dec 31PMID 42417704Review
- Transdermal versus oral hormone replacement therapy and bone mass density in Turner syndrome patients: a pilot studyGynecol Endocrinol2026 Dec 31PMID 42351362
- Recent advances in the relationship between mental symptoms in postmenopausal women and estrogen fluctuationsJ Psychosom Obstet Gynaecol2026 Dec 31PMID 42100911Review
- A randomized controlled trial on the effect of Gushukang on bone mineral density in perimenopausal and postmenopausal womenGynecol Endocrinol2026 Dec 31PMID 42033017RCT
- Protocol flexibility in PCOS: a combination of controlled ovarian stimulation and endometrial preparation strategies shows no impact on live birth outcomes after frozen embryo transfer-a retrospective cohort studyGynecol Endocrinol2026 Dec 31PMID 41934169
- Intrauterine platelet-rich plasma infusion with hormone replacement therapy improves menstrual and pregnancy outcomes in thin endometrium patients undergoing frozen-thawed embryo transferGynecol Endocrinol2026 Dec 31PMID 41493055
- Menopausal Experience in Solid-Organ Transplant RecipientsProg Transplant2026 DecPMID 42684863
- Physiology of menopause and the role of hormone therapyAdv Physiol Educ2026 Dec 1PMID 42661457Review
More endocrinology trends
All specialties →Oral GLP-1 drugs
Oral semaglutide and small-molecule GLP-1 agonists such as orforglipron.
Key point: In adults with obesity or overweight and type 2 diabetes, once-daily orforglipron reduced bodyweight versus placebo, with safety similar to other GLP-1 agonists.
Automated insulin delivery
Hybrid closed-loop systems that adjust insulin automatically.
Primary aldosteronism
Screening, diagnosis and treatment of primary aldosteronism.
Key point: Universal screening for primary aldosteronism in all patients with hypertension with an aldosterone-to-renin ratio test is now recommended.
Thyroid eye disease
Thyroid eye disease and targeted treatments such as teprotumumab.
Key point: IGF-1R inhibitors outperformed placebo across multiple thyroid eye disease efficacy outcomes, particularly in active disease, but increased adverse-event risk warrants vigilant monitoring.
CGM in type 2 diabetes
Continuous glucose monitoring for people with type 2 diabetes.
Key point: CGM is strongly recommended for people with type 2 diabetes treated with insulin and those not treated with insulin, particularly when HbA1c is ≥7%.
Anabolic osteoporosis treatment
Romosozumab, abaloparatide and teriparatide for osteoporosis.
Key point: Abaloparatide has efficacy and safety similar to teriparatide and represents a new option for patients with severe osteoporosis and very high fracture risk.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
"menopausal hormone therapy"[tiab] OR "hormone replacement therapy"[tiab]Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.